Navigation Links
Equashield's Sales Grow by 60% in 2013

PORT WASHINGTON, New York, January 14, 2014 /PRNewswire/ --

Equashield (, the leading provider of Closed System Transfer Devices (CSTD) for hazardous drugs, today announced that it has achieved 60% year-over-year sales growth for the fourth straight year.  

Equashield's closed systems reduce the risk of exposure for pharmacy technicians, pharmacists, nurses and other medical professionals who prepare and administer hazardous drugs, such as chemotherapy. In addition, the solution helps to prevent microbial ingress, decreasing the risk of infection in patients receiving these drugs.

"Approximately 20% of hospitals and medical centers are already investing in closed systems to ensure their employees' safety," said Marino Kriheli, Product Manager at Equashield. "With growing awareness of the many risks associated with hazardous drug exposure, this market is rapidly growing. In fact, 55% of new customers Equashield acquired this year did not use closed systems previously. Furthermore, with the recent launch of Equashield II, the company's second generation CSTD, we expect major sales growth to continue in 2014 and beyond."

Equashield is the only preassembled closed syringe that requires no further setup, making it quicker and easier to use than other system on the market. Equashield devices are currently used in the Cleveland Clinic, Mt. Sinai Hospital in New York and hundreds of other medical facilities.

Equashield II covers more routes of exposure to hazardous drugs than alternative systems and is the only system that prevents contamination of syringe plungers by hazardous drugs.

"Contamination on syringe plungers has been clearly identified in recent studies, added Kriheli. "The quantities of drug residue found on plungers place this route of exposure among the top risks associated with handling hazardous drugs."

About Equashield

Equashield is a leading developer of closed system drug transfer devices that protect healthcare professionals from hazardous drug and vapor exposure. EQUASHIELD® provides superior safety & ease-of-use by covering more routes of exposure than alternative systems and by enabling faster use than other systems. EQUASHIELD® is clinically proven to eliminate surface contamination with antineoplastic agents and prevent microbial ingress, having demonstrated the ability to extend beyond-use dating for single-use or non-preserved drugs. The system consists of a unique syringe with encapsulated barrel and plunger, built-in closed pressure equalization, and an integrated single motion connector that remains free of drug residue even after multiple connections. EQUASHIELD® is the only preassembled CSTD syringe on the market that requires no further setup, thereby contributing to ease of use and overall hospital productivity. For more information, visit

Media Contact:
Finn Partners for Equashield
Ellie Hanson

SOURCE Equashield
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardica Appoints Industry Veteran Liam Burns As Vice President, Sales And Marketing
2. AMRI Hires George Svokos as Senior Vice President Sales and General Manager - API
3. FPR Specialty Pharmacy Hires Slomski To Lead Sales And Marketing; Moves To Next Phase In Cleveland Clinic Trials
4. Simbionix Welcomes New Latin and Central American Sales Manager
5. Immunotherapies Will Continue to Dominate the Malignant Melanoma Drug Market with Sales of Immune Checkpoint Inhibitors Accounting for Majority of Sales in this Drug Class in 2022
6. TRU-D SmartUVC Sales Soar in 2013 with Increased Acceptance of Proven Infection Prevention Technology
7. Indegene Named a Leader in IDC MarketScape: Worldwide Life Science Sales and Marketing BPO 2013 Vendor Assessment
8. Vermillion Appoints Marian E. Sacco as SVP of Sales and Marketing and Chief Commercial Officer
9. The Chronic Pain Drug Market Will Attain $21.6 Billion in Major-Market Sales by 2022
10. Osseon Announces New Regional Sales Director
11. Cantel Medical Reports 19% Sales Growth And EPS Of $0.27 vs. $0.23 For The First Quarter Ended October 31, 2013
Post Your Comments:
(Date:11/26/2015)... 2015 Research and Markets ( ) has ... Market Outlook to 2019 - Rise in Cardiac Disorders and ... report to their offering. Boston ... scientific and others. --> The ... Boston scientific and others. ...
(Date:11/26/2015)... , November 26, 2015 ... of the "2016 Future Horizons and ... Abuse Testing Market: Supplier Shares, Country Segment ... to their offering. --> ... "2016 Future Horizons and Growth Strategies ...
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda SyMRI ... (MR-bilder) för patienter med multipel skleros ... forskningsavtal med SyntheticMR AB för att kunna ... på sjukhuset. Med SyMRI kan man generera ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you ... for not only fulfilling the needs of advisers and clients but going above ... and providing top-tier customer service. However, there's always room for improvement, which is ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... largest, most successful and prominent nonprofit healthcare organizations in the country. They have ... with various organizations, and helped advance the healthcare industry as a whole through ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... center software Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term Support) ... supported Asterisk 11 LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk ...
(Date:11/26/2015)... ON (PRWEB) , ... November 26, 2015 , ... ... of a real-time eReferral system for diagnostic imaging in the Waterloo region. Using ... BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) without ...
(Date:11/26/2015)... ... 26, 2015 , ... Jobs in hospital medical laboratories and in the imaging ... staffing agency Aureus Medical Group . These fields, as well as ... searching for healthcare jobs through the company’s website, , The leading ...
Breaking Medicine News(10 mins):